Canurta Therapeutics | Ontario, Canada | Botanical Drug Development
For decades, a specific problem stalled an entire branch of pharmaceutical research.
Certain rare polyphenols found in plants — cannflavins among them — had shown enough biological activity to interest scientists. But they occur in vanishingly small quantities. Producing enough to run a serious study, let alone a clinical trial, was impractical. The compounds were interesting and effectively unobtainable, which in drug development amounts to the same thing as not existing.
In 2019, a laboratory at the University of Guelph solved that.
Dr. Tariq Akhtar and his team developed a patented method to efficiently extract and enrich rare polyphenols including cannflavins A and B. It was a supply breakthrough rather than a medical one, and it was exactly the kind of breakthrough the field had been waiting for. Compounds that could not previously be studied at scale suddenly could be.
Canurta Therapeutics was founded in 2021 to build on that discovery.
A Different Theory of How to Treat Complex Disease
The company’s scientific premise is worth setting out carefully, because it runs against how most modern drugs are designed.
Conventional pharmaceutical development favours single-target therapies: identify one mechanism, design a molecule that acts on it precisely, and measure the result. That approach has produced enormous successes, particularly where a disease has a clear single driver.
Canurta’s position is that some diseases do not work that way. Neurological and inflammatory conditions, including amyotrophic lateral sclerosis, are driven by a web of interconnected biological pathways — which makes them difficult to address with single-target therapies. The company’s research into bioactive compounds points toward their ability to interact with multiple systems, modulating processes such as inflammation, oxidative stress and cell survival.
Its lead candidate, CNR-401, embodies that strategy by targeting multiple mechanisms implicated in ALS. The company’s stated aim for its botanical therapies is to slow disease progression, relieve symptoms and improve quality of life across ALS and a broader range of neurodegenerative and inflammatory conditions.
This is early-stage science, and the company presents it as such — a clinical-stage pipeline of botanical drug candidates progressing toward pivotal trials.
PolyKye™: Finding the Right Molecule Faster
The technical asset that makes the approach practical is PolyKye™, launched in 2023 — a predictive AI and bioinformatics engine built to accelerate polyphenol-based drug discovery.
The platform rapidly identifies novel bioactives to guide compound selection, disease pathway targeting and advanced formulation.
The reason this matters is a question of scale. Plants produce thousands of polyphenols, most of which have never been characterized. Testing them empirically, one at a time, against multiple disease pathways is a search space no laboratory can exhaust. A predictive model that narrows the field before the bench work begins changes what is discoverable within a company’s lifetime.
It also reflects a serious commitment. Canurta reached 23 global patents filed across 7 major markets by 2023, spanning manufacturing, AI-driven discovery, therapeutic compositions and biosynthetic innovations. For a company founded two years earlier, that is an unusual rate of intellectual property development, and it indicates the platform is treated as a core asset rather than a research convenience.
A Board That Has Done This Before
The single most striking thing about Canurta is who agreed to advise it.
The company built its scientific advisory board in 2022, appointing former GW Pharmaceuticals leadership and senior regulatory experts. GW Pharmaceuticals is the company that took Sativex® and Epidiolex® through development and regulatory approval — the clearest precedent anywhere for bringing a plant-derived medicine through the pharmaceutical system.
Dr. Ethan Russo, M.D., serves as Senior Medical Advisor: a clinician-scientist specializing in plant-based therapeutics, with 16 years at GW Pharmaceuticals and a role as study physician for the Sativex® and Epidiolex® clinical trials. Alan Sutton advises on CMC, bringing over two decades at GW. Matthew Hersh and Steve Crow both contribute clinical operations expertise developed over 20-plus years at GW and Jazz Pharmaceuticals.
Alongside them sit Dr. Neal Davies, Dean and Professor in the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta and a leading investigator of anti-inflammatory and anti-cancer nutraceuticals including flavonoids; Dr. José Casaretto, a research scientist and inventor on extraction and biosynthesis patents; and Dr. Tariq Akhtar himself, the University of Guelph associate professor whose laboratory produced the original breakthrough, serving as Principal Investigator for molecule development.
That is a formidable group, and its composition addresses the central difficulty in this field. Botanical drug development fails most often not on the science but on chemistry, manufacturing and controls, regulatory strategy and trial design — the disciplines where a plant-derived product must demonstrate the consistency regulators require. Canurta has recruited people who have already navigated exactly that.
The company is led by CEO and Founder Akeem Gardner, whose background in law, psychology and philosophy shapes his focus on strategic direction, intellectual property development and commercialization. The internal team includes Kelly Boddington, Ph.D., whose biochemistry expertise covers polyphenol synthesis; Eric Soubeyrand, Ph.D., a plant biology and secondary metabolism specialist with over 20 publications; Pamela Kisun, Head of Operations, leading clinical operations, SOP implementation and GxP compliance; and Samantha Palloo, People and Culture Lead, who has secured over $400,000 in government grants.
Building the Path to Market
The company has surpassed $18 million in total funding, including $3.22 million in non-dilutive funding directed at formulation, AI and regulatory programs.
Its ecosystem partners read as a map of Canadian research infrastructure: the Government of Canada, NRC IRAP, Mitacs, Ontario Centres of Excellence, BioTalent Canada, ECO Canada, Foodpreneur Lab and Blue Green Clinical.
Recent moves have focused on the route to market. In 2025 Canurta entered a definitive agreement with PharmaDrug Inc., advancing a public-market strategy and support for CNR-401’s clinical and commercial pathway, and signed a letter of intent with extractX Ltd. to scale botanical input processing and accelerate drug supply chain readiness.
That second agreement is quietly significant. A botanical drug requires a reliable, consistent supply of plant material processed to pharmaceutical standards — a problem that has ended promising programs before they reached the clinic. Addressing it ahead of pivotal trials is the mark of a team that has seen where these projects fail.
What Comes Next
Recent activity includes the launch of PolyKye Formulations™, the conclusion of SOVEREIGN 2026, and newly published research, including a study examining whether hemp flavonoids may play a protective role in cartilage.
The wider context is favourable. Regulatory frameworks for botanical drugs are better established than they were a decade ago, largely because of the precedents the company’s own advisors helped set. AI-assisted discovery has matured into a genuine research instrument. And the therapeutic areas Canurta has chosen — ALS and neurodegenerative and inflammatory disease — remain among the most underserved in medicine.
From a discovery in a Guelph laboratory to a clinical-stage pipeline, advised by the people who brought the world’s first plant-derived prescription medicines to market.
Your role in staying up to date is integral to our shared mission of fostering a community of innovators. CanadianSME Magazine is a valuable treasure trove of entrepreneurial knowledge. Click here to subscribe to our monthly editions for updates on Canadian businesses. Follow our handle @canadian_sme on X to remain updated on all business trends and developments. Your support is crucial to our mission.
Disclaimer: This article is based on publicly available information intended only for informational purposes. CanadianSME Small Business Magazine does not endorse or guarantee any products or services mentioned. Readers are advised to conduct their research and due diligence before making business decisions.
